ATE544463T1 - Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen - Google Patents

Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen

Info

Publication number
ATE544463T1
ATE544463T1 AT05851326T AT05851326T ATE544463T1 AT E544463 T1 ATE544463 T1 AT E544463T1 AT 05851326 T AT05851326 T AT 05851326T AT 05851326 T AT05851326 T AT 05851326T AT E544463 T1 ATE544463 T1 AT E544463T1
Authority
AT
Austria
Prior art keywords
scf
treatment
polypeptide
brain
combination
Prior art date
Application number
AT05851326T
Other languages
English (en)
Inventor
Li-Ru Zhao
John Kessler
Seema Singhal
Mehta Jayesh
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Application granted granted Critical
Publication of ATE544463T1 publication Critical patent/ATE544463T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05851326T 2004-11-05 2005-11-04 Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen ATE544463T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62518904P 2004-11-05 2004-11-05
PCT/US2005/039792 WO2006055260A2 (en) 2004-11-05 2005-11-04 Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders

Publications (1)

Publication Number Publication Date
ATE544463T1 true ATE544463T1 (de) 2012-02-15

Family

ID=36407603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05851326T ATE544463T1 (de) 2004-11-05 2005-11-04 Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen

Country Status (6)

Country Link
US (2) US20060153799A1 (de)
EP (1) EP1817047B1 (de)
AT (1) ATE544463T1 (de)
AU (1) AU2005306894B2 (de)
CA (1) CA2586365A1 (de)
WO (1) WO2006055260A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009517343A (ja) * 2005-11-14 2009-04-30 エンタープライズ パートナーズ ベンチャー キャピタル 組織損傷のための幹細胞因子療法
DE102006004142A1 (de) * 2006-01-27 2007-08-02 Axaron Bioscience Ag Neue therapeutische Indikationen von Koloniestimulierenden Faktoren
US9770485B2 (en) * 2006-02-21 2017-09-26 Academia Sinica Methods for rescuing learning and/or memory deficits caused by alzheimer's disease by G-CSF
US7618938B2 (en) * 2007-02-07 2009-11-17 Academia Sinica Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly
MX2011001486A (es) 2008-08-05 2011-05-02 Univ South Florida El uso de mediadores inflamatorios en el tratamiento del deterioro cognotivo.
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
KR20100020125A (ko) * 2008-08-12 2010-02-22 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 신경병증성 통증 예방 또는치료제
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
CA2842969C (en) 2011-07-25 2018-03-27 Generon (Shanghai) Corporation Ltd. Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases
CN107267449B (zh) * 2013-02-06 2021-03-19 Nc医学研究公司 用于治疗神经变性的细胞疗法
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
US10039808B2 (en) 2014-10-22 2018-08-07 Michael Chez Method of treating or improving neurological function in a human subject
US9925244B1 (en) 2015-02-17 2018-03-27 Michael Chez Treatment of warts in non-immunosuppressed patients
WO2019200240A1 (en) 2018-04-13 2019-10-17 Board Of Regents, The University Of Texas System Transmembrane stem cell factor (tm-scf) lipid nanocarriers and methods of use thereof
WO2023158681A1 (en) * 2022-02-16 2023-08-24 Vasogenesis Inc. Methods of using a blood cell growth factor to treat impaired blood flow

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
JPH01500483A (ja) 1986-08-11 1989-02-23 シタス　コーポレイション Ｇ‐ｃｓｆ及びそのミューテインの発現
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
FI900178A0 (fi) 1988-05-13 1990-01-12 Amgen Inc Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur.
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE464482C (sv) 1989-08-25 1997-09-08 Teknoskand Invent Ab Med spärr försett svängarmsbeslag till fönster, luckor o d
JPH04502164A (ja) * 1989-10-10 1992-04-16 アムジエン・インコーポレーテツド 犬科・猫科動物における感染の治療または予防のための化学組成物及び方法
US6248319B1 (en) * 1989-10-16 2001-06-19 Krisztina M. Zsebo Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
RU2212411C2 (ru) 1989-10-16 2003-09-20 Эмджен Инк. Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты)
US6204363B1 (en) * 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
DK0423980T3 (da) * 1989-10-16 2000-10-09 Amgen Inc Stamcellefaktor
US6207454B1 (en) * 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
JPH04164098A (ja) 1990-03-07 1992-06-09 Kirin Amgen Inc 化学修飾顆粒球コロニー刺激因子誘導体
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5241072A (en) 1990-05-25 1993-08-31 Genzyne Corporation Oligosaccharide oxazolines, oligosaccharide conjugates and methods of preparation thereof
WO1992000376A1 (en) 1990-06-25 1992-01-09 Immunex Corporation Mast cell growth factor
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
DK0546124T4 (da) 1990-08-29 2003-05-19 Inst Genetics Llc Hæmatopoiese-stimulatorer med flere domæner
JPH05502463A (ja) 1990-09-28 1993-04-28 オーソ・フアーマシユーチカル・コーポレーシヨン ハイブリツド成長因子
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
ATE173763T1 (de) 1991-08-30 1998-12-15 Hutchinson Fred Cancer Res Hybride cytokine
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
DE69521880T2 (de) 1994-02-08 2002-01-03 Amgen Inc., Thousand Oaks Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
US5525708A (en) 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
WO1999017798A1 (en) 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
CA2395713C (en) 2000-01-10 2012-04-10 Maxygen, Inc. G-csf conjugates
DE10033219A1 (de) * 2000-07-07 2002-01-24 Univ Heidelberg Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF)
ATE468862T1 (de) 2001-07-11 2010-06-15 Maxygen Inc G-csf konjugate
WO2003030821A2 (en) 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
US7605128B2 (en) * 2002-02-14 2009-10-20 Buck Institute For Age Research Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia
US20060246036A1 (en) * 2002-09-06 2006-11-02 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors

Also Published As

Publication number Publication date
EP1817047A2 (de) 2007-08-15
AU2005306894B2 (en) 2011-11-24
US8524655B2 (en) 2013-09-03
EP1817047B1 (de) 2012-02-08
AU2005306894A1 (en) 2006-05-26
CA2586365A1 (en) 2006-05-26
WO2006055260A3 (en) 2006-07-27
WO2006055260A2 (en) 2006-05-26
US20060153799A1 (en) 2006-07-13
US20100286039A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
WO2008097861A3 (en) MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
ATE521608T1 (de) Glucokinaseaktivatoren
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
WO2006055260A3 (en) Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
CY1108927T1 (el) Αναστολεις μιτωτικης κινεσινης
EP2377530A3 (de) Modulation von Neurogenese durch PDE-Hemmung
MY148985A (en) 2-aminopyridine analogs as glucokinase activators
EA201270591A1 (ru) ДВУЗАМЕЩЕННЫЕ ОКТАГИДРОПИРРОЛ[3,4-c]ПИРРОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ
WO2008021196A3 (en) Methods and compositions for the treatment of medical disorders
MY151018A (en) Use of nutritional compositions for preventing disorders
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
WO2007134077A3 (en) 5 ht receptor mediated neurogenesis
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
IL250832B (en) A mixture of beta-glycosylceramide and beta-lactosylceramide for use in the treatment of colitis
EP2698166A3 (de) Komplementhemmung für verbesserte Nervenregeneration
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
WO2007098091A3 (en) Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
WO2005113590A3 (en) Bmp10 propeptides and related methods
TW200744629A (en) Treatments for neurological disorders
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2017190044A8 (en) Methods for detecting and treating pain using brain activity
WO2006105359A3 (en) Methods for stimulating hair growth by administering bmps
JP2006512419A5 (de)
DK2714888T3 (da) Rekombinant gær
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones